PharmaLegacy provides preclinical in vivo pharmacology efficacy services as well a therapeutic antibody discovery service program. Our state-of-the-art platforms include
• Pioneering work using CD34+ humanized mice that carry a human immune system, to test biologics for immuno-oncology therapeutic efficacy
• An NHP platform for therapeutic biologics testing in a variety of immune diseases
• An advanced antibody discovery platform based on single B cell antibody sequencing
• An internationally recognized Bone/Orthopaedics platform to test both hard tissue disease therapeutic candidates and medical devices
We have over 300 clinically predictive animal disease models to evaluate pharmacological effects of drug candidates in the areas of inflammation/auto-Immune diseases, lung injury, liver/metabolic diseases and oncology.
Our NHP platform and CD34+ humanized mice models have helped dozens of clients with IND filings to both FDA and CFDA (China) for their therapeutic biologics candidates in a variety of immune disease and oncology. Our animal vivarium is fully accredited by AAALAC and houses species ranging from rodents, rabbits and other small animals to NHP.